{"url_path":"/sec/zvsa/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1859007/0001493152-26-022759-index.html","accession_number":"0001493152-26-022759","cik":"0001859007","ticker":"ZVSA","issuer_name":"ZyVersa Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1859007/0001493152-26-022759-index.html","primary_entity_key":"0001859007","primary_entity_name":"ZyVersa Therapeutics, Inc."},"word_count":514,"has_tables":true,"body_markdown":"**ITEM\n6. EXHIBITS.**\n\n \n\n**Exhibit**\n \n**Description**\n\n3.1\n \n[Second Amended and Restated Certificate of Incorporation of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022).](https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/ex3-1.htm)\n\n3.2\n \n[Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 30, 2023).](https://www.sec.gov/Archives/edgar/data/1859007/000149315223043170/ex3-1.htm)\n\n3.3\n \n[Second Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 25, 2024).](https://www.sec.gov/Archives/edgar/data/1859007/000149315224015938/ex3-1.htm)\n\n3.4\n \n[Second Amended and Restated Bylaws of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022).](https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/ex3-2.htm)\n\n3.5\n \n[Certificate of Designation relating to the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022).](https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/ex3-3.htm)\n\n4.1\n \n[Form of Series A-4 Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 5, 2026).](https://www.sec.gov/Archives/edgar/data/1859007/000149315226008994/ex4-1.htm)\n\n10.1#\n \n[Securities Purchase Agreement, dated February 26, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 5, 2026).](https://www.sec.gov/Archives/edgar/data/1859007/000149315226008994/ex10-1.htm)\n\n10.2\n \n[Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 5, 2026).](https://www.sec.gov/Archives/edgar/data/1859007/000149315226008994/ex10-2.htm)\n\n31.1*\n \n[Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).](ex31-1.htm)\n\n31.2*\n \n[Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).](ex31-2.htm)\n\n32.1**\n \n[Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350.](ex32-1.htm)\n\n101.INS**\n \nXBRL\nInline Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within\nthe Inline XBRL document).\n\n101.SCH*\n \nInline\nXBRL Taxonomy Extension Schema Document.\n\n101.CAL*\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document.\n\n101.DEF*\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document.\n\n101.LAB*\n \nInline\nXBRL Taxonomy Extension Label Linkbase Document.\n\n101.PRE*\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document.\n\n104*\n \nCover\nPage Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101).\n\n \n\n*\nFiled herewith.\n\n**\nFurnished herewith.\n\n# The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation\nS-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange\nCommission upon request.\n\n \n\n22\n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report to be signed on its\nbehalf by the undersigned hereunto duly authorized.\n\n \n\nDated:\nMay 13, 2026\nBy:\n*/s/\nStephen C, Glover*\n\n \n \nStephen\nC. Glover\n\n \n \nChief\nExecutive Officer\n\n \n \n(Principal\nExecutive Officer)\n\n \n \n \n\nDated:\nMay 13, 2026\nBy:\n*/s/\nPeter Wolfe*\n\n \n \nPeter\nWolfe\n\n \n \nChief\nFinancial Officer\n\n \n \n(Principal\nFinancial and Accounting Officer)\n\n \n\n23"}